OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.
Optimizing Genomic Testing for Antibiotic Resistance
Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.
Deaths each year from bacterial infections (WHO)
Deaths annually in the us & europe from drug-resistant infections
Excess direct healthcare costs in the us from drug-resistant infections
OpGen Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in COVID-19 Pneumonia Patients and Presents Data on Unyvero HPN Panel at ECCVID 2020 MORE
OpGen, Inc. Announces Notice of Annual Meeting Venue Change MORE
Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing MORE
There are currently no upcoming events.
Latest Blog Posts
A Multiplex Polymerase Chain Reaction Assay for Antibiotic Stewardship in Suspected Pneumonia MORE
New Antibiotics won’t solve the Antibiotic Resistance Crisis, but better Diagnostics could MORE
Assessing the Potential of Short-Read and Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results in Carbapenem-Resistant Klebsiella pneumoniae MORE